Related Experiment Video
Updated: Mar 15, 2026
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
Published on: March 1, 2019
Development of a VLP-based vaccine in silkworm pupae against rabbit hemorrhagic disease virus
Xuexing Zheng1, Shukun Wang2, Weijiao Zhang3
1School of Public Health, Shandong University, Jinan 250012, China; China Biotechnology Research Institute, Chinese Academy of Agricultural Sciences, Beijing 10081, China.
Abstract:
Rabbit hemorrhagic disease virus (RHDV) is the etiological agent behind rabbit hemorrhagic disease (RHD), which is lethal and contagious in rabbits. The virus does not replicate in cell culture and the only commercial inactivated vaccine available is derived from infected rabbit livers. RHDV capsid protein, VP60, is the main antigen comprising the virion. We used a baculovirus-silkworm pupae system to express VP60, which self-assembled into virus-like particles (VLPs) with a similar size and morphology to RHDV. Hemagglutination assays (HAs) showed that VP60 expression levels of VP60 reached as high as 107HA units (HAU) per pupa. A single intramuscular injection with 104HAU of VLPs completely protected rabbits for at least 180days against RHDV challenge, and for at least 360days when the VLPs were emulsified with Freund's complete adjuvant. These data suggest that silkworm pupae can be used to develop VLP-based vaccines which confer durable protection against RHD.
More Related Videos
08:10Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
Published on: January 15, 2020
05:36Author Spotlight: Advancing Gene Silencing Research in Silkworms with dsRNA Delivery Through Feeding Chitosan Nanoparticles
Published on: October 4, 2024